Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study
{"title":"Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study","authors":"Bingfu Wang, Yulong Song, Yujian Fan, Zhiqiang Zhao","doi":"10.1155/cdr/1649836","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Although laxatives are commonly used for constipation in critically ill patients with acute myocardial infarction (AMI), the optimal initial choice is unclear. We are aimed at comparing the clinical outcomes of initiating therapy with stimulant, stool softener, and osmotic laxatives.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study analyzed ICU patients with AMI from the MIMIC-IV database, comparing three initial laxative strategies using propensity score matching (PSM). The primary outcome was 28-day mortality. Secondary outcomes included ICU, in-hospital, and 365-day mortality; cardiogenic shock; malignant arrhythmia; delirium; and bowel sound recovery. Findings were validated with inverse probability of treatment weighting (IPTW) and subgroup analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In the 1:1:1 PSM cohort of 1887 patients, stool softeners were associated with significantly lower mortality versus stimulants: in-hospital (adjusted OR = 0.39, 95% CI 0.22–0.69, p = 0.001), 28-day (aHR = 0.55, 95% CI 0.40–0.76, p < 0.001), and 365-day (aHR = 0.57, 95% CI 0.45–0.72, p < 0.001). Osmotic laxatives correlated with lower in-hospital (aOR = 0.52, 95% CI 0.30–0.89, p = 0.017) and 28-day (aHR = 0.72, 95% CI 0.55–0.95, p = 0.019) mortality, but not 365-day compared with stimulant laxatives. Both agents were linked to lower delirium risk and better bowel sound recovery. IPTW sensitivity analyses showed consistent results.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Among ICU-admitted AMI patients, the initial use of stool softeners or osmotic laxatives was associated with a lower risk of short-term mortality compared with stimulant laxatives. These findings indicate that a more robust and gentle laxative management strategy may have potential clinical value for this high-risk population.</p>\n </section>\n </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069469/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/1649836","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Although laxatives are commonly used for constipation in critically ill patients with acute myocardial infarction (AMI), the optimal initial choice is unclear. We are aimed at comparing the clinical outcomes of initiating therapy with stimulant, stool softener, and osmotic laxatives.
Methods
This retrospective study analyzed ICU patients with AMI from the MIMIC-IV database, comparing three initial laxative strategies using propensity score matching (PSM). The primary outcome was 28-day mortality. Secondary outcomes included ICU, in-hospital, and 365-day mortality; cardiogenic shock; malignant arrhythmia; delirium; and bowel sound recovery. Findings were validated with inverse probability of treatment weighting (IPTW) and subgroup analyses.
Results
In the 1:1:1 PSM cohort of 1887 patients, stool softeners were associated with significantly lower mortality versus stimulants: in-hospital (adjusted OR = 0.39, 95% CI 0.22–0.69, p = 0.001), 28-day (aHR = 0.55, 95% CI 0.40–0.76, p < 0.001), and 365-day (aHR = 0.57, 95% CI 0.45–0.72, p < 0.001). Osmotic laxatives correlated with lower in-hospital (aOR = 0.52, 95% CI 0.30–0.89, p = 0.017) and 28-day (aHR = 0.72, 95% CI 0.55–0.95, p = 0.019) mortality, but not 365-day compared with stimulant laxatives. Both agents were linked to lower delirium risk and better bowel sound recovery. IPTW sensitivity analyses showed consistent results.
Conclusion
Among ICU-admitted AMI patients, the initial use of stool softeners or osmotic laxatives was associated with a lower risk of short-term mortality compared with stimulant laxatives. These findings indicate that a more robust and gentle laxative management strategy may have potential clinical value for this high-risk population.
背景:虽然泻药常用于急性心肌梗死(AMI)重症患者的便秘,但最初的最佳选择尚不清楚。我们的目的是比较启动治疗与兴奋剂,大便软化剂和渗透性泻药的临床结果。方法:回顾性分析MIMIC-IV数据库中ICU AMI患者,采用倾向评分匹配(PSM)比较三种初始泻药策略。主要终点为28天死亡率。次要结局包括ICU、住院和365天死亡率;心原性休克;恶性心律失常;精神错乱;肠音恢复。研究结果通过治疗加权逆概率(IPTW)和亚组分析进行验证。结果:在1887例1:1:1 PSM患者队列中,与兴奋剂相比,大便软化剂的死亡率显著降低:住院(调整OR = 0.39, 95% CI 0.22-0.69, p = 0.001)、28天(aHR = 0.55, 95% CI 0.40-0.76, p < 0.001)和365天(aHR = 0.57, 95% CI 0.45-0.72, p < 0.001)。渗透性泻药与较低的住院死亡率(aOR = 0.52, 95% CI 0.30-0.89, p = 0.017)和28天死亡率(aHR = 0.72, 95% CI 0.55-0.95, p = 0.019)相关,但与刺激性泻药相比,365天死亡率不相关。这两种药物都与较低的谵妄风险和更好的肠道声音恢复有关。IPTW敏感性分析结果一致。结论:在icu住院的AMI患者中,与刺激性泻药相比,最初使用大便软化剂或渗透性泻药与较低的短期死亡率相关。这些发现表明,一种更加稳健和温和的泻药管理策略可能对这一高危人群具有潜在的临床价值。
期刊介绍:
Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged.
Subject areas include (but are by no means limited to):
Acute coronary syndrome
Arrhythmias
Atherosclerosis
Basic cardiac electrophysiology
Cardiac catheterization
Cardiac remodeling
Coagulation and thrombosis
Diabetic cardiovascular disease
Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF)
Hyperlipidemia
Hypertension
Ischemic heart disease
Vascular biology
Ventricular assist devices
Molecular cardio-biology
Myocardial regeneration
Lipoprotein metabolism
Radial artery access
Percutaneous coronary intervention
Transcatheter aortic and mitral valve replacement.